Louisiana-Pacific Corporation enters the week after earnings with a meaningful short book, a decisive shift in options tone, and a Street that remains constructive but is steadily trimming its price targets.
Short interest is genuinely elevated — and has been building. SI % FF has climbed from roughly 8.5% in late March to just under 9.5% now, a move of about one percentage point over six weeks that represents an 11% rise in absolute short shares over the past month. The peak came in mid-April, when SI touched nearly 10% of the float, before easing slightly through late April; it has since stabilised around 9.5%. At those levels, this is a stock that bears have been actively positioning into — not a marginal short. The FINRA fortnightly data puts days-to-cover at 7.1, so unwinding would not be quick.
The borrow market tells a less alarming story. Availability is running at over 1,200% of short interest — far above the threshold where squeezes become a real risk — and cost to borrow, while up roughly 16% on the week, is only 0.47% annualised. That's cheap. The availability signal says there is no pressure on the lending pool, and any new short can be established without difficulty. Worth noting: the ORTEX short score is hovering around 51, close to neutral, and has been drifting down from a peak of around 52 in mid-April — consistent with shorts trimming at the margin rather than pressing.
Options positioning has swung sharply bullish in the past two weeks, and the contrast with the short book is striking. The put/call ratio has collapsed to 0.38, well below its 20-day average of 0.63 and near the lowest reading of the past year (the 52-week floor is 0.19). For most of March and into April, PCR was running near 0.98 — effectively a one-for-one put/call balance that reflected genuine caution. That has reversed almost entirely. Options traders are now leaning heavily toward calls, a setup that sits roughly 0.8 standard deviations below the recent mean. The sharp PCR drop coincides with the stock's post-earnings bounce — up 1.1% on May 5 — suggesting that some investors moved from hedges to upside bets once the earnings event cleared.
The Street broadly endorses the thesis but has been cutting price targets for months. DA Davidson maintained its Buy and $114 target in a note published May 5 — the day the stock traded at $69.75 — implying over 60% upside from the current price. Barclays held its Overweight in April but cut its target from $104 to $90. BMO lowered its Market Perform target from $98 to $94 in late April. The mean analyst target is $94.75, about 36% above current levels, which is a wide gap. No analyst has turned negative in the recent run of changes; the direction is lower targets, not lower ratings. The bull case rests on the siding segment's long-cycle growth and geographic expansion; bears point to housing cyclicality, OSB weakness, and commodity input volatility. On valuation, the stock trades at 22x trailing earnings and roughly 10.6x EV/EBITDA — both multiples that have compressed modestly over the past month. The EPS surprise factor score ranks at the 97th percentile, indicating a strong track record of beating estimates, though EPS momentum scores of 25 and 15 over 30 and 90 days suggest forward revisions have been running soft.
Berkshire Hathaway remains the most watched name in the institutional register, holding just over 8% of shares with no change reported through December 2025. Vanguard and BlackRock hold similar stakes and have both been adding modestly. On the insider side, the most consequential recent move was a $1.7 million open-market purchase by independent director Nicholas Grasberger III in February at $85.49 — now well above the current price at $69.75. The CEO sold shares in mid-February, also above current levels. Taken together, the insider picture in the window since January reflects net selling at higher prices, with one director making a meaningful contrarian bet that is currently underwater.
Peers have had a rough week across the board. WFG fell 7.2% over five days, IFP dropped 10%, and CLW shed 8.5% — so LPX's 7.8% weekly decline was consistent with broad sector weakness rather than a stock-specific dislocation. The next watch point is whether the PCR stays at its current bullish extreme or reverts as near-term options positions roll, and whether short interest continues the modest easing trend that began after touching the mid-April peak near 10% of the float.
See the live data behind this article on ORTEX.
Open LPX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
